NIH 2017 N43 HL |
Igf::Ot::Igf Price, Robert / Technolgy Holding, LLC |
|
NIH 2017 N43 HL |
Igf::Ot::Igf Shandler, Scott / Longevity Biotech, Inc. |
|
NIH 2016 N43 HL |
IGF::OT::IGF SBIR Topic #97, Phase I, Cardiotoxicity Biomarker Sensing Device Chao, Chung-Yen / Physical Optics Corporation |
|
NIH 2016 N43 HL |
Igf::Ot::Igf SBIR Topic 096:the Development Leading to the Commercialization of A Bioresorbable Stents (BRS) for the Treatment of Coarctation of the Aorta in Neonates Can# 16-8470256 Palasis, Maria / 480 Biomedical, Inc. |
|
NIH 2016 N43 HL |
IGF::OT::IGF The development leading to the commercialization of a bioresorbable stents (BRS) for the treatment of coarctation of the aorta (COA) in neonates. Moran, Tim / |
|
NIH 2015 N43 HL |
Igf::Ot::Igf Rd - Therapeutic Delivery of Adp-Ribosylarginine Hydrolase, SBIR Topic 91, Phase I Chen, Chen / Protein Foundry, LLC |
|
NIH 2015 N43 HL |
Igf::Ot::Igf:: SBIR Topic 089 Phase I - IN-Bore Defibrillation for Invasive Cardiology Procedures Shusterman, Vladimir / Pinmed, Inc. |
|
NIH 2015 N43 HL |
Igf::Ot::Igf SBIR Topic 87: Fast Track, Base (Phase I)(Line Item 1) Cerclage for Treating Secondary Mitral Regurgitation Rafiee, Nasser / Transmural Systems, LLC |
|
NIH 2015 N43 HL |
Igf::Ot::Igf R&D Lubock, Paul / |
|